Feng Lei

Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary ...

Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreat...

Camrelizumab plus gemcitabine-cisplatine als eerstelijns bij NPC: CAPTAIN-1st fase III